Endothelial Nitric Oxide Synthase in Vascular Disease
Top Cited Papers
- 4 April 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 113 (13) , 1708-1714
- https://doi.org/10.1161/circulationaha.105.602532
Abstract
Nitric oxide (NO·) is an important protective molecule in the vasculature, and endothelial NO· synthase (eNOS) is responsible for most of the vascular NO· produced. A functional eNOS oxidizes its substratel-arginine tol-citrulline and NO·. This normal function of eNOS requires dimerization of the enzyme, the presence of the substratel-arginine, and the essential cofactor (6R)-5,6,7,8-tetrahydro-l-biopterin (BH4), one of the most potent naturally occurring reducing agents. Cardiovascular risk factors such as hypertension, hypercholesterolemia, diabetes mellitus, or chronic smoking stimulate the production of reactive oxygen species in the vascular wall. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidases represent major sources of this reactive oxygen species and have been found upregulated and activated in animal models of hypertension, diabetes, and sedentary lifestyle and in patients with cardiovascular risk factors. Superoxide (O2·−) reacts avidly with vascular NO· to form peroxynitrite (ONOO−). The cofactor BH4is highly sensitive to oxidation by ONOO−. Diminished levels of BH4promote O2·−production by eNOS (referred to as eNOS uncoupling). This transformation of eNOS from a protective enzyme to a contributor to oxidative stress has been observed in several in vitro models, in animal models of cardiovascular diseases, and in patients with cardiovascular risk factors. In many cases, supplementation with BH4has been shown to correct eNOS dysfunction in animal models and patients. In addition, folic acid and infusions of vitamin C are able to restore eNOS functionality, most probably by enhancing BH4levels as well.Keywords
This publication has 40 references indexed in Scilit:
- Effects of supplemental oxygen administration on coronary blood flow in patients undergoing cardiac catheterizationAmerican Journal of Physiology-Heart and Circulatory Physiology, 2005
- Upregulation of Vascular Arginase in Hypertension Decreases Nitric Oxide–Mediated Dilation of Coronary ArteriolesHypertension, 2004
- Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertensionThe FASEB Journal, 2004
- Ischemia‐reperfusion selectively impairs nitric oxide‐ mediated dilation in coronary arterioles: counteracting role of arginaseThe FASEB Journal, 2003
- Superoxide Production and Expression of Nox Family Proteins in Human AtherosclerosisCirculation, 2002
- Increased Expression of Arginase II in Human Diabetic Corpus Cavernosum: In Diabetic-Associated Erectile DysfunctionBiochemical and Biophysical Research Communications, 2001
- Oxidation of Tetrahydrobiopterin by Peroxynitrite: Implications for Vascular Endothelial FunctionBiochemical and Biophysical Research Communications, 1999
- Crystal Structure of Constitutive Endothelial Nitric Oxide Synthase: A Paradigm for Pterin Function Involving a Novel Metal CenterCell, 1998
- Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions.Hypertension, 1994
- Effects of L-arginine on forearm vessels and responses to acetylcholine.Hypertension, 1992